Investigational drug · Phase 2
ACP-211
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ACP-211"
First trial start
2025
Nov 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACP-211", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder (MDD)
- Depressive Disorder, Treatment-Resistant
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ACP-211" as an intervention, largest first.
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponsePivotal-lookingRecruiting
ACADIA Pharmaceuticals Inc.Industry
NCT07284667 · 153 participants (planned) · Start Nov 14, 2025 · Primary completion Aug 2027
Drug: ACP-211; Placebo · For: Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant
Sites: Birmingham, Alabama; Chino, California; Glendale, California · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Major Depressive Disorder (MDD)
- KH607Phase 34 trials
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
- Bupropion Sustained-ReleasePhase 31 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- SPT-300LYT-300, GlyphAlloPhase 22 trials
Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- NH102Phase 21 trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- SPN-821Phase 21 trial
Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.